{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:31:42Z","timestamp":1789443102210,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00296-013-2778-0","type":"journal-article","created":{"date-parts":[[2013,5,13]],"date-time":"2013-05-13T05:34:37Z","timestamp":1368423277000},"page":"429-433","source":"Crossref","is-referenced-by-count":18,"title":["Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"34","author":[{"given":"Tsuyoshi","family":"Kasama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Isojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayu","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,14]]},"reference":[{"issue":"3","key":"2778_CR1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/BOR.0b013e32805e87f1","volume":"19","author":"F Brennan","year":"2007","unstructured":"Brennan F, Beech J (2007) Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 19(3):296\u2013301","journal-title":"Curr Opin Rheumatol"},{"key":"2778_CR2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2741\/s53","volume":"2","author":"Z Szekanecz","year":"2010","unstructured":"Szekanecz Z, Vegvari A, Szabo Z, Koch AE (2010) Chemokines and chemokine receptors in arthritis. Front Biosci (Schol Ed) 2:153\u2013167","journal-title":"Front Biosci (Schol Ed)"},{"issue":"23","key":"2778_CR3","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205\u20132219","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"2778_CR4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar1969","volume":"8","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, Maini RN (2006) Interleukin-6: a new therapeutic target. Arthritis Res Ther 8(Suppl 2):S5","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"2778_CR5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","volume":"2","author":"N Nishimoto","year":"2006","unstructured":"Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2(11):619\u2013626","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"11","key":"2778_CR6","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ard.2010.134684","volume":"69","author":"IB McInnes","year":"2010","unstructured":"McInnes IB, O\u2019Dell JR (2010) State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 69(11):1898\u20131906","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2778_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2778_CR8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","volume":"49","author":"DM Heijde van der","year":"1990","unstructured":"van der Heijde DM, van\u2019t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49(11):916\u2013920","journal-title":"Ann Rheum Dis"},{"key":"2778_CR9","first-page":"S869","volume":"63","author":"D Aletaha","year":"2011","unstructured":"Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS (2011) Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Arthritis Rheum 63:S869","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2778_CR10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nri1200","volume":"3","author":"T Calandra","year":"2003","unstructured":"Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3(10):791\u2013800","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2778_CR11","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B","volume":"42","author":"M Leech","year":"1999","unstructured":"Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42(8):1601\u20131608","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2778_CR12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2029","volume":"5","author":"EF Morand","year":"2006","unstructured":"Morand EF, Leech M, Bernhagen J (2006) MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5(5):399\u2013410","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"2778_CR13","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.185.8.1455","volume":"185","author":"HY Lan","year":"1997","unstructured":"Lan HY, Bacher M, Yang N, Mu W, Nikolic-Paterson DJ, Metz C, Meinhardt A, Bucala R, Atkins RC (1997) The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 185(8):1455\u20131465","journal-title":"J Exp Med"},{"issue":"7","key":"2778_CR14","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.4049\/jimmunol.177.7.4818","volume":"177","author":"ML Toh","year":"2006","unstructured":"Toh ML, Aeberli D, Lacey D, Yang Y, Santos LL, Clarkson M, Sharma L, Clyne C, Morand EF (2006) Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol 177(7):4818\u20134825","journal-title":"J Immunol"},{"issue":"8","key":"2778_CR15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/ard.61.8.723","volume":"61","author":"V Pittoni","year":"2002","unstructured":"Pittoni V, Bombardieri M, Spinelli FR, Scrivo R, Alessandri C, Conti F, Spadaro A, Valesini G (2002) Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 61(8):723\u2013725","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2778_CR16","first-page":"36","volume":"52","author":"PA Klimiuk","year":"2004","unstructured":"Klimiuk PA, Sierakowski S, Domyslawska I, Fiedorczyk M, Chwiecko J (2004) Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp (Warsz) 52(1):36\u201342","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"5","key":"2778_CR17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00296-006-0241-1","volume":"27","author":"Y Kageyama","year":"2007","unstructured":"Kageyama Y, Torikai E, Nagano A (2007) Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int 27(5):467\u2013472","journal-title":"Rheumatol Int"},{"issue":"6","key":"2778_CR18","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3899\/jrheum.081074","volume":"36","author":"T Odai","year":"2009","unstructured":"Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Miwa Y, Kasama T (2009) Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 36(6):1158\u20131165","journal-title":"J Rheumatol"},{"key":"2778_CR19","first-page":"19","volume":"1","author":"T Kasama","year":"2010","unstructured":"Kasama T, Sato M, Takahashi R, Odai T, Kobayashi K (2010) The CX3CL1\/CX3CR1 axis is a sensitive marker of the response to anti-TNF therapy in patients with rheumatoid arthritis. J Clin Rheumatol Musculoskel Med 1:19\u201325","journal-title":"J Clin Rheumatol Musculoskel Med"},{"issue":"4","key":"2778_CR20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00296-009-1299-3","volume":"31","author":"PA Klimiuk","year":"2011","unstructured":"Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J (2011) Serum chemokines in patients with rheumatoid arthritis treated with etanercept. Rheumatol Int 31(4):457\u2013461","journal-title":"Rheumatol Int"},{"issue":"8","key":"2778_CR21","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/ard.2007.086728","volume":"68","author":"CA Wijbrandts","year":"2009","unstructured":"Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes EG, Kastelein JJ, Tak PP (2009) Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 68(8):1316\u20131321","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2778-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-013-2778-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2778-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:21:47Z","timestamp":1559028107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-013-2778-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,14]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["2778"],"URL":"https:\/\/doi.org\/10.1007\/s00296-013-2778-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,14]]}}}